Enobia Pharma has completed patient enrolment for a Phase II study evaluating ENB-0040 as a treatment for hypophosphatasia, a rare metabolic bone disorder.
The study will evaluate ENB-0040 in adolescents and adults with the comdition. On its completion, which is anticipated later this year, the company will have collected safety and efficacy data for ENB-0040 in hypophosphatasia patients of all ages.
ENB-0040 was granted orphan designation in the US and EU in 2008 and fast-track status in 2009. If approved, it would be the first treatment for hypophosphatasia.
Hypophosphatasia is a rare genetic disease characterised primarily by defective bone mineralisation caused by a deficiency in the enzyme tissue non-specific alkaline phosphatase.